The sudden withdrawal of Heidi Overton's nomination leaves the nation's premier health regulator searching for a commissioner amid critical drug reviews. Compounding the regulatory shifts, the agency rejected a closely watched lung cancer treatment developed jointly by U.S.-based Summit Therapeutics and Chinese company Akeso. Concurrently, a new index by STAT was launched to rank China's leading pharmaceutical and biotechnology firms. This tracking highlights the expanding footprint and market influence of Chinese drug developers worldwide.
Key points
The Food and Drug Administration remains without confirmed leadership following a sudden…: The Food and Drug Administration remains without confirmed leadership following a sudden nomination withdrawal.
A prominent cross-border cancer drug collaboration suffered a setback from federal regula…: A prominent cross-border cancer drug collaboration suffered a setback from federal regulators.
Global tracking of major Chinese pharmaceutical firms is expanding through dedicated indu…: Global tracking of major Chinese pharmaceutical firms is expanding through dedicated industry indexes.
Sources checked by our analysis pipeline: 1
On this week’s episode of “The Readout LOUD”: The FDA is once again searching for a new leader, a closely tracked lung cancer drug suffers an FDA rejection, and China’s largest drugmakers ranked.
We invite you to listen to this pre-Thanksgiving episode of your favorite biotech podcast, where our attention turns to D.C. The Trump administration withdrew the nomination of Heidi Overton to become the next FDA commissioner hours before a pivotal Senate committee vote. STAT’s D.C. correspondent Margaret Manto joins us to explain why Overton was tossed and who might be next in line to run the FDA.
We’ll also chatter away about this week’s news, including the FDA’s rejection of a lung cancer drug from the U.S.-based biotech Summit Therapeutics and the Chinese drug maker Akeso. And speaking of China, STAT just launched a new index ranking China’s largest drugmakers. We’ll discuss how the list was made and why tracking Chinese biotech has become so important.
Make sure to subscribe to “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.
Muhammad Yusuf Zainol pleaded guilty following a workplace altercation at a Tuas company that left a subordinate with lasting physical impairments. The physical confrontation began after a miscommunication over moving a vehicle escalated into a verbal dispute. Due to the severe trauma inflicted by the shove, the injured worker underwent surgery and faces permanent nerve complications.
Residents in Brookline, Massachusetts, are facing unexpected strikes from a defensive bird that has targeted pedestrians from behind without warning. Local law enforcement has consulted state wildlife authorities to handle the unusual situation safely while adhering to environmental regulations. Because native raptors are legally protected throughout the state, officials must balance public safety precautions with wildlife conservation laws.
Clinical researchers evaluating daraxonrasib reported that the targeted oral therapy successfully halted tumour progression in 90% of advanced-stage participants. Designed to disable driver mutations common in difficult-to-treat malignancies, the medication significantly outpaced standard chemotherapy survival benchmarks during trial monitoring. These early outcomes offer an unprecedented therapeutic option for patients dealing with previously uncontrollable metastatic spread.